Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It also offers IT service related to healthcare; and disease risk testing services. In addition, the company is involved with research and development of diagnostic drugs; and planning, development and OEM manufacturing of health food, pharmaceuticals, general food and other products. The company was founded in 1951 and is headquartered in Osaka, Japan.
Stock data | 2023 | Change |
---|---|---|
Price | $19.73 | N/A |
Market Cap | $971.24M | N/A |
Shares Outstanding | 49.22M | 0.01% |
Employees | 4.30K | N/A |
Shareholder Equity | 136.89B | 3.57% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | 0.44 | N/A |
P/S Ratio | 0.67 | N/A |
P/B Ratio | 0.01 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.0001 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $1.45B | N/A |
Earnings | $15.24M | N/A |
EPS | 44.72 | N/A |
Earnings Yield | 2.27 | N/A |
Gross Margin | 0.3481 | N/A |
Operating Margin | 0.0264 | N/A |
Net income margin | 0.0105 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $2.57B | N/A |
Total Debt | $1.20B | N/A |
Cash on Hand | $168.00M | N/A |
Debt to Equity | 0.0119 | 13.22% |
Cash to Debt | 0.1402 | -38.47% |
Current Ratio | $2.33 | 60.70% |